Exercise of Camurus’ subscription warrant program 2020/2023
Lund, Sweden — 25 August 2023 — During August 2023, a total of 80,325 subscription warrants in Camurus AB’s warrant program 2020/2023 have been exercised for the corresponding number of shares, at an exercise price of SEK 169.50 per share. Through the exercise of the subscription warrants Camurus receives SEK 13,615,037.50.
A number of employees and senior executives of Camurus have participated with own financing and in a cashless exercise, where shares have been sold to finance the subscription of new shares and taxes related to the transaction. As a result of the transactions, the total shareholdings of the senior executives of Camurus have increased with net 1,000 shares, corresponding to 0.1 percent of their total holdings.
The exercise period for warrant program 2020/2023 ends on 15 December 2023.
For more information
Fredrik Tiberg, President & CEO
Tel. +46 (0)46 286 46 92
[email protected]
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
[email protected]
About Camurus
Camurus is a Swedish, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com.
The information was submitted for publication at 07:00 am CET on 25 August 2023.
